{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,24]],"date-time":"2025-08-24T01:11:52Z","timestamp":1755997912150,"version":"3.41.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T00:00:00Z","timestamp":1751414400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T00:00:00Z","timestamp":1751414400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s00280-025-04793-6","type":"journal-article","created":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T06:08:59Z","timestamp":1751436539000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Trends in renal function following vascular endothelial growth factor inhibitor administration in patients with cancer and diabetes mellitus"],"prefix":"10.1007","volume":"95","author":[{"given":"Yuma","family":"Shibutani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miki","family":"Hayakawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mayu","family":"Ishizaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,2]]},"reference":[{"key":"4793_CR1","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1016\/j.mcna.2023.03.007","volume":"107","author":"N Yarandi","year":"2023","unstructured":"Yarandi N, Shirali AC (2023) Onco-nephrology: kidney disease in a cancer patient. Med Clin North Am 107:749\u2013762. https:\/\/doi.org\/10.1016\/j.mcna.2023.03.007","journal-title":"Med Clin North Am"},{"key":"4793_CR2","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1056\/NEJMoa2214963","volume":"388","author":"GW Prager","year":"2023","unstructured":"Prager GW, Taieb J, Fakih M, Ciardiello F, Van Cutsem E, Elez E, Cruz FM, Wyrwicz L, Stroyakovskiy D, P\u00e1pai Z et al (2023) Trifluridine-tipiracil and bevacizumab in refractory metastatic colorectal cancer. N Engl J Med 388:1657\u20131667. https:\/\/doi.org\/10.1056\/NEJMoa2214963","journal-title":"N Engl J Med"},{"key":"4793_CR3","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1056\/NEJMoa1406470","volume":"372","author":"M Schlumberger","year":"2015","unstructured":"Schlumberger M, Tahara M, Wirth LJ, Robinson B, Brose MS, Elisei R, Habra MA, Newbold K, Shah MH, Hoff AO et al (2015) Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med 372:621\u2013630. https:\/\/doi.org\/10.1056\/NEJMoa1406470","journal-title":"N Engl J Med"},{"key":"4793_CR4","doi-asserted-by":"publisher","first-page":"1814","DOI":"10.1056\/NEJMoa1510016","volume":"373","author":"TK Choueiri","year":"2015","unstructured":"Choueiri TK, Escudier B, Powles T, Mainwaring PN, Rini BI, Donskov F, Hammers H, Hutson TE, Lee JL, Peltola K et al (2015) Cabozantinib versus everolimus in advanced Renal-Cell carcinoma. N Engl J Med 373:1814\u20131823. https:\/\/doi.org\/10.1056\/NEJMoa1510016","journal-title":"N Engl J Med"},{"key":"4793_CR5","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s40620-016-0311-8","volume":"30","author":"L Cosmai","year":"2017","unstructured":"Cosmai L, Gallieni MC et al (2017) Renal toxicity of anticancer agents targeting vascular endothelial growth factor (VEGF) and its receptors (VEGFRs). J Nephrol 30:171\u2013180. https:\/\/doi.org\/10.1007\/s40620-016-0311-8","journal-title":"J Nephrol"},{"key":"4793_CR6","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1016\/j.cell.2019.01.021","volume":"176","author":"RS Apte","year":"2019","unstructured":"Apte RS, Chen DS, Ferrara N (2019) VEGF in signaling and disease: beyond discovery and development. Cell 176:1248\u20131264. https:\/\/doi.org\/10.1016\/j.cell.2019.01.021","journal-title":"Cell"},{"key":"4793_CR7","doi-asserted-by":"publisher","first-page":"100620","DOI":"10.1016\/j.ctarc.2022.100620","volume":"32","author":"TC Elebiyo","year":"2022","unstructured":"Elebiyo TC, Rotimi D, Evbuomwan IO, Maimako RF, Iyobhebhe M, Ojo OA, Oluba OM, Adeyemi OS (2022) Reassessing vascular endothelial growth factor (VEGF) in anti-angiogenic cancer therapy. Cancer Treat Res Commun 32:100620. https:\/\/doi.org\/10.1016\/j.ctarc.2022.100620","journal-title":"Cancer Treat Res Commun"},{"key":"4793_CR8","doi-asserted-by":"publisher","first-page":"640","DOI":"10.3390\/diagnostics11040640","volume":"11","author":"M Van Wynsberghe","year":"2021","unstructured":"Van Wynsberghe M, Flejeo J, Sakhi H, Ollero M, Sahali D, Izzedine H, Henique C (2021) Nephrotoxicity of anti-angiogenic therapies. Diagnostics (Basel) 11:640. https:\/\/doi.org\/10.3390\/diagnostics11040640","journal-title":"Diagnostics (Basel)"},{"key":"4793_CR9","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1056\/NEJMoa2108330","volume":"386","author":"V Makker","year":"2022","unstructured":"Makker V, Colombo N, Casado Herr\u00e1ez A, Santin AD, Colomba E, Miller DS, Fujiwara K, Pignata S, Baron-Hay S, Ray-Coquard I et al (2022) Lenvatinib plus pembrolizumab for advanced endometrial cancer. N Engl J Med 386:437\u2013448. https:\/\/doi.org\/10.1056\/NEJMoa2108330","journal-title":"N Engl J Med"},{"key":"4793_CR10","doi-asserted-by":"publisher","first-page":"5536","DOI":"10.3390\/cancers13215536","volume":"13","author":"T Enokida","year":"2021","unstructured":"Enokida T, Tahara M (2021) Management of VEGFR-targeted TKI for thyroid cancer. Cancers (Basel) 13:5536. https:\/\/doi.org\/10.3390\/cancers13215536","journal-title":"Cancers (Basel)"},{"key":"4793_CR11","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/S1470-2045(15)70127-0","volume":"16","author":"J Tabernero","year":"2015","unstructured":"Tabernero J, Yoshino T, Cohn AL, Obermannova R, Bodoky G, Garcia-Carbonero R, Ciuleanu TE, Portnoy DC, Van Cutsem E, Grothey A et al (2015) Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): A randomised, double-blind, multicentre, phase 3 study. Lancet Oncol 16:499\u2013508. https:\/\/doi.org\/10.1016\/S1470-2045(15)70127-0","journal-title":"Lancet Oncol"},{"key":"4793_CR12","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","volume":"382","author":"RS Finn","year":"2020","unstructured":"Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, Kudo M, Breder V, Merle P, Kaseb AO et al (2020) Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med 382:1894\u20131905. https:\/\/doi.org\/10.1056\/NEJMoa1915745","journal-title":"N Engl J Med"},{"key":"4793_CR13","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/dom.14007","volume":"1","author":"NM Selby","year":"2020","unstructured":"Selby NM, Taal MW (2020) An updated overview of diabetic nephropathy: diagnosis, prognosis, treatment goals and latest guidelines. Diabetes Obes Metab 22 Suppl 1:3\u201315. https:\/\/doi.org\/10.1111\/dom.14007","journal-title":"Diabetes Obes Metab 22 Suppl"},{"key":"4793_CR14","doi-asserted-by":"publisher","unstructured":"Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, Yamagata K, Tomino Y, Yokoyama H, Hishida A Collaborators developing the Japanese equation for estimated GFR (2009) revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 53:982\u2013992. https:\/\/doi.org\/10.1053\/j.ajkd.2008.12.034","DOI":"10.1053\/j.ajkd.2008.12.034"},{"key":"4793_CR15","doi-asserted-by":"publisher","first-page":"e17588","DOI":"10.1097\/MD.0000000000017588","volume":"98","author":"H Iwasaki","year":"2019","unstructured":"Iwasaki H, Yamazaki H, Takasaki H, Suganuma N, Sakai R, Nakayama H, Toda S, Masudo K (2019) Renal dysfunction in patients with radioactive iodine-refractory thyroid cancer treated with tyrosine kinase inhibitors: A retrospective study. Med (Baltim) 98:e17588. https:\/\/doi.org\/10.1097\/MD.0000000000017588","journal-title":"Med (Baltim)"},{"key":"4793_CR16","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1186\/s12885-021-08622-w","volume":"21","author":"C Masaki","year":"2021","unstructured":"Masaki C, Sugino K, Kobayashi S, Hosoi Y, Ono R, Yamazaki H, Akaishi J, Hames KY, Tomoda C, Suzuki A et al (2021) Impact of lenvatinib on renal function: Long-term analysis of differentiated thyroid cancer patients. BMC Cancer 21:894. https:\/\/doi.org\/10.1186\/s12885-021-08622-w","journal-title":"BMC Cancer"},{"key":"4793_CR17","doi-asserted-by":"publisher","first-page":"1154771","DOI":"10.3389\/fonc.2023.1154771","volume":"13","author":"Y Shibutani","year":"2023","unstructured":"Shibutani Y, Suzuki S, Sagara A, Enokida T, Okano S, Fujisawa T, Sato F, Yumoto T, Sano M, Kawasaki T, Tahara M (2023) Impact of lenvatinib-induced proteinuria and renal dysfunction in patients with thyroid cancer. Front Oncol 13:1154771. https:\/\/doi.org\/10.3389\/fonc.2023.1154771","journal-title":"Front Oncol"},{"key":"4793_CR18","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1111\/jdi.13625","volume":"13","author":"T Muramatsu","year":"2022","unstructured":"Muramatsu T, Takahashi M, Kakinuma R, Sato T, Yamamoto M, Akazawa M, Tanaka K, Kikuchi T, Kushiyama A (2022) Decline in renal function associated with cardiovascular autonomic neuropathy positively coordinated with proteinuria in patients with type 2 diabetes. J Diabetes Investig 13:102\u2013111. https:\/\/doi.org\/10.1111\/jdi.13625","journal-title":"J Diabetes Investig"},{"key":"4793_CR19","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1681\/ASN.2018080853","volume":"30","author":"CC Estrada","year":"2019","unstructured":"Estrada CC, Maldonado A, Mallipattu SK (2019) Therapeutic Inhibition of VEGF signaling and associated nephrotoxicities. J Am Soc Nephrol 30:187\u2013200. https:\/\/doi.org\/10.1681\/ASN.2018080853","journal-title":"J Am Soc Nephrol"},{"key":"4793_CR20","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1038\/s41581-021-00462-y","volume":"17","author":"M Oshima","year":"2021","unstructured":"Oshima M, Shimizu M, Yamanouchi M, Toyama T, Hara A, Furuichi K, Wada T (2021) Trajectories of kidney function in diabetes: A clinicopathological update. Nat Rev Nephrol 17:740\u2013750. https:\/\/doi.org\/10.1038\/s41581-021-00462-y","journal-title":"Nat Rev Nephrol"},{"key":"4793_CR21","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1007\/s10147-024-02474-7","volume":"29","author":"S Kataoka","year":"2024","unstructured":"Kataoka S, Nishikawa Y, Funakoshi T, Horimatsu T, Sakuragi M, Uchino E, Hiragi S, Yamamoto S, Sakai K, Matsubara T et al (2024) Proteinuria frequency and subsequent renal dysfunction in bevacizumab-treated patients: A single center, retrospective, observational study. Int J Clin Oncol 29:398\u2013406. https:\/\/doi.org\/10.1007\/s10147-024-02474-7","journal-title":"Int J Clin Oncol"},{"key":"4793_CR22","doi-asserted-by":"publisher","first-page":"e16236","DOI":"10.1097\/MD.0000000000016236","volume":"98","author":"T Fujii","year":"2019","unstructured":"Fujii T, Kawasoe K, Tonooka A, Ohta A, Nitta K (2019) Nephrotic syndrome associated with ramucirumab therapy: A single-center case series and literature review. Med (Baltim) 98:e16236. https:\/\/doi.org\/10.1097\/MD.0000000000016236","journal-title":"Med (Baltim)"},{"key":"4793_CR23","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1093\/ndtplus\/sfn168","volume":"2","author":"AL Uy","year":"2009","unstructured":"Uy AL, Simper NB, Champeaux AL, Perkins RM (2009) Progressive bevacizumab-associated renal thrombotic microangiopathy. NDT Plus 2:36\u201339. https:\/\/doi.org\/10.1093\/ndtplus\/sfn168","journal-title":"NDT Plus"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-025-04793-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-025-04793-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-025-04793-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T06:09:00Z","timestamp":1751436540000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-025-04793-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,2]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["4793"],"URL":"https:\/\/doi.org\/10.1007\/s00280-025-04793-6","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,2]]},"assertion":[{"value":"1 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no potential conflicts of interest with respect to the research, authorship, or publication of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The requirement for informed consent was waived because the study was conducted according to a retrospective chart review protocol.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"This study was approved by the Review Committee of the National Cancer Center (Research Project No. 2023\u2009\u2212\u2009244).","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical considerations"}}],"article-number":"69"}}